

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

1-9. (canceled)

10. (Previously Presented) A complex of a ligand and a polypeptide, wherein the polypeptide comprises the isolated amino acid sequence selected from (i) the amino acids 40-60 of SEQ ID NO:7 (mouse synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain) and (ii) the amino acids 40-60 of SEQ ID NO:9 (rat synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain), wherein the ligand is BoNT/B and binds to the polypeptide at amino acids 40 to 60 of SEQ ID NO:7 or SEQ ID NO:9.

11-41. (canceled)

42. (Previously Presented) The complex of claim 10, wherein the polypeptide is a synthetic or recombinant peptide.

43. (Previously Presented) The complex of claim 10, wherein the polypeptide comprises a luminal domain of the rat or mouse synaptotagmin II.

44. (Previously Presented) The complex of claim 42, wherein the polypeptide consists of the BoNT/B-binding domain and optionally further consists of an affinity tag.

45-46. (canceled)

47. (Previously Presented) A complex of a ligand and a polypeptide, wherein the polypeptide comprises the amino acid sequence (i) the amino acids 40 to 60 of SEQ ID NO:7 (mouse synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain) or (ii) the amino acids 40 to 60 of SEQ ID NO:9 (rat synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain), wherein the ligand is an antibody that binds to the polypeptide at amino acids 40 to 60 of SEQ ID NO:7 or SEQ ID NO:9 and reduces binding of BoNT/B to the polypeptide, and wherein the complex is located *in vivo* in a mammal.

48. (Previously Presented) The complex of claim 10, wherein the polypeptide further comprises a binding site for a ganglioside.

49. (Previously Presented) The complex of claim 47, wherein the polypeptide is a recombinant polypeptide.

50-68. (canceled)

69. (Previously Presented) A complex of a ligand and a polypeptide, wherein the polypeptide comprises the amino acid sequence selected from (i) the amino acids 40-60 of SEQ ID NO:7 (mouse synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain) and (ii) the amino acids 40-60 of SEQ ID NO:9 (rat synaptotagmin II botulinum toxin serotype B (BoNT/B)-binding domain), wherein the ligand is an antibody against said amino acid sequence, and binds to the polypeptide at amino acids 40 to 60 of SEQ ID NO:7 or SEQ ID NO:9, thereby reducing binding of BoNT/B to the polypeptide.

70. (Previously Presented) The complex of claim 69, wherein the polypeptide further comprises a binding site for a ganglioside.